Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

Summary

Narrative review written as a primer for orthopaedic surgeons and sports medicine physicians on popular injectable peptides. Based on a PubMed literature search of biochemical and clinical studies, it evaluates BPC-157, TB-4 (thymosin beta 4), TB-500, CJC-1295 + ipamorelin, tesamorelin and GHK-Cu. For TB-500, it finds preclinical support for tissue repair but no human orthopaedic data.

Key Findings

• TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models
• Human orthopaedic data for TB-4 and TB-500 are lacking
• Both TB-4 and TB-500 remain banned substances in sports
• Across the peptides reviewed, the indications, dosing, frequency and duration of treatment remain unknown
• The authors conclude that significant safety and efficacy research is needed before definitive recommendations can be made to patients

Relevance to TB-500

Places TB-500 within a 2026 orthopaedic-journal assessment of injectable peptides. It confirms preclinical promise for angiogenesis and tissue repair while stating plainly that human orthopaedic data are lacking and that TB-500 is banned in sport. Important context for TB-500’s evidence level relative to other healing peptides. The same review also covers BPC-157, CJC-1295, Ipamorelin and GHK-Cu.

Citation

Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Am J Sports Med. 2026;54(1):223-229. doi: 10.1177/03635465251357593. PMID: 41476424

See Also

• Parent compound: TB-500
• BPC-157
• GHK-Cu